William Blair Weighs in on Agenus' Q3 Earnings (NASDAQ:AGEN)

Key Points

• William Blair has revised down its Q3 2025 earnings per share estimate for Agenus to ($0.98), from a previous forecast of ($0.65).
• Agenus reported Q2 earnings of ($1.00) per share, missing consensus estimates of ($0.78), with revenues of $25.70 million, significantly below expectations of $49.71 million.
• Currently, Agenus has a consensus rating of Moderate Buy among analysts, with an average price target of $15.50.

Agenus Inc. (NASDAQ:AGEN - Free Report) - Research analysts at William Blair cut their Q3 2025 earnings per share (EPS) estimates for shares of Agenus in a research report issued to clients and investors on Tuesday, August 12th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($0.98) per share for the quarter, down from their prior estimate of ($0.65). The consensus estimate for Agenus' current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus' Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($4.06) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.62) EPS and FY2027 earnings at ($3.61) EPS.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million during the quarter, compared to analyst estimates of $49.71 million.

Other research analysts have also issued reports about the company. B. Riley reissued a "buy" rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright raised Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price on the stock in a report on Wednesday, June 4th. Robert W. Baird upped their price objective on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. Wall Street Zen lowered Agenus from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Zacks Research raised Agenus to a "hold" rating in a report on Tuesday, August 12th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Agenus presently has an average rating of "Hold" and an average target price of $15.50.

Agenus Stock Down 2.2%

Shares of AGEN stock traded down $0.10 during trading on Friday, reaching $4.53. 247,683 shares of the company's stock were exchanged, compared to its average volume of 703,343. The stock has a market capitalization of $144.33 million, a PE ratio of -0.63 and a beta of 1.62. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34. The firm's fifty day moving average price is $5.34 and its 200-day moving average price is $3.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. B. Riley Financial Inc. acquired a new position in Agenus in the 4th quarter valued at $2,074,000. Siren L.L.C. acquired a new stake in shares of Agenus during the 1st quarter worth $752,000. Marshall Wace LLP acquired a new stake in shares of Agenus during the 2nd quarter worth $1,976,000. AQR Capital Management LLC grew its holdings in shares of Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock worth $664,000 after purchasing an additional 427,604 shares in the last quarter. Finally, Gilead Sciences Inc. acquired a new stake in shares of Agenus during the 4th quarter worth $635,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.